BioLife Solutions, Inc.

Equities

BLFS

US09062W2044

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
17.53 ^USD	+3.97%		+10.53%	+7.88%

Apr. 18	BioLife Solutions Completes Divestment of Global Cooling Subsidiary	MT
Apr. 18	An undisclosed buyer entered into a Stock Purchase Agreement to acquire Global Cooling, Inc. from BioLife Solutions, Inc. for $2.6 million.	CI

BioLife Solutions, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

February 29, 2024 at 05:16 pm EST

BioLife Solutions, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was USD 8.03 million compared to USD 10.45 million a year ago. Revenue was USD 143.27 million compared to USD 161.76 million a year ago.

Net loss was USD 66.43 million compared to USD 139.81 million a year ago. Basic loss per share from continuing operations was USD 1.52 compared to USD 3.29 a year ago. Diluted loss per share from continuing operations was USD 1.52 compared to USD 3.29 a year ago.

Latest news about BioLife Solutions, Inc.

BioLife Solutions Completes Divestment of Global Cooling Subsidiary	Apr. 18	MT
An undisclosed buyer entered into a Stock Purchase Agreement to acquire Global Cooling, Inc. from BioLife Solutions, Inc. for $2.6 million.	Apr. 17	CI
Jefferies Initiates Coverage on BioLife Solutions With Buy Rating, $22 Price Target	Apr. 04	MT
BioLife Solutions, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Transcript : BioLife Solutions, Inc., Q4 2023 Earnings Call, Feb 29, 2024	Feb. 29
BioLife Solutions, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI
Biolife Solutions Announces Preliminary Unaudited Revenue Results for Fourth Quarter and Full Year 2023	Jan. 08	CI
Lake Street Adjusts BioLife Solutions Price Target to $15 From $25, Maintains Buy Rating	Nov. 10	MT
Transcript : BioLife Solutions, Inc., Q3 2023 Earnings Call, Nov 09, 2023	Nov. 09
BioLife Solutions, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Casdin Capital Engages in Discussions with BioLife Solutions	23-10-24	CI
BioLife Solutions Names New CEO; Sees 2023 Revenue at Low End of Guidance	23-10-19	MT
BioLife Solutions, Inc. Announces Chief Executive Officer Changes	23-10-19	CI
BioLife Solutions, Inc. Announces Management Changes	23-10-19	CI
BioLife Solutions, Inc. Revises Earnings Guidance for the Full Year 2023	23-10-19	CI
BioLife Solutions, Inc. announced that it has received $10.374976 million in funding from Casdin Capital, LLC	23-10-18	CI
Lake Street Adjusts Price Target on BioLife Solutions to $25 From $34, Maintains Buy Rating	23-08-09	MT
Transcript : BioLife Solutions, Inc., Q2 2023 Earnings Call, Aug 08, 2023	23-08-08
Biolife Solutions, Inc. Provides Earnings Guidance for the Year 2023	23-08-08	CI
BioLife Solutions, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-08	CI
Stephens Adjusts BioLife Solutions Price Target to $29 From $27, Maintains Overweight Rating	23-07-17	MT
Craig-Hallum Starts BioLife Solutions at Buy With $29 Price Target	23-07-11	MT
Insider Sell: Biolife Solutions	23-06-23	MT
BioLife Solutions Says SciSafe Facilities in US Received Accreditation From College of American Pathologists	23-06-14	MT
BioLife Solutions, Inc. Launches the IntelliRate i67C Liquid Nitrogen Controlled-Rate Freezer	23-06-06	CI

Chart BioLife Solutions, Inc.

Duration

Period

More charts

Company Profile

BioLife Solutions, Inc. is a supplier of cell processing tools and services for the cell and gene therapy (CGT) and broader biopharma markets. Its expertise facilitates the commercialization of new therapies by supplying solutions that maintain the health and function of biologic materials during collection, development, storage and distribution. Its biopreservation media products, HypoThermosol FRS and CryoStor Freeze Media, are formulated to mitigate preservation-induced, delayed-onset cell damage and death which result when cells and tissues are subjected to reduced temperatures. Its bioproduction tools portfolio includes human platelet lysates for cell expansion. It is a provider of biological and pharmaceutical storage and cold chain logistics. Its monitoring systems allow customers real time tracking of the storage temperatures of their materials throughout the logistics process. It operates about five storage facilities in the United States and one facility in the Netherlands.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for BioLife Solutions, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

17.53 USD

Average target price

23.12 USD

Spread / Average Target

+31.92%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
BIOLIFE SOLUTIONS, INC.	+7.88%	794M
ABBOTT LABORATORIES	-2.31%	187B
MEDTRONIC PLC	-3.20%	106B
BECTON, DICKINSON AND COMPANY	-5.04%	66.9B
DEXCOM, INC.	+0.20%	49.45B
CENCORA, INC.	+17.29%	48B
HOYA CORPORATION	+4.06%	40.84B
METTLER-TOLEDO INTERNATIONAL, INC.	+2.07%	26.48B
WEST PHARMACEUTICAL SERVICES, INC.	+2.36%	26.25B
TERUMO CORPORATION	+12.96%	24.62B

Other Medical Equipment, Supplies & Distribution